The current study explored whether patient characteristics predicted patterns of antidepressant use (i.e., never used, single episode of use, or two or more episodes) in a naturalistic follow-up. Participants in the child/adolescent multimodal (CAMS) extended long-term study. (n = 318) indicated medication use over the course of eight follow-up visits, 3–12 years after receiving treatment in CAMS. 40.6% of participants reported never using an antidepressant during follow-up, 41.4% reported a single episode of antidepressant use, and 18.0% reported multiple episodes of antidepressant use. Greater baseline anxiety severity marginally predicted a single episode of antidepressant use; baseline depression severity predicted multiple episodes of use. Reasons for discontinuing antidepressants included perceived ineffectiveness (31.8%), side effects (25.5%), and improvement in symptoms (18.5%). Exploratory analyses examined predictors of medication use. Findings suggest that antidepressant use is common among anxious youth, as is discontinuation of antidepressant use. Clinical implications and future directions are discussed.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Medications in this category included SSRIs, SNRIs, and related medications, including Sertraline, Fluoxetine, Citalopram, Escitalopram, Paroxetine, Fluvoxamine, Venlafaxine, Desvenlafaxine, Duloxetine, and Bupropion.
CAMELS participants were more likely to be female, of non-Hispanic ethnicity, and of higher SES than non-participants. Among those who completed less than three visits 12.7% (n = 8) were Hispanic; 49.2% (n = 31) were female, and 28.6% (n = 18) were of lower SES.
Some participants endorsed both stopping one antidepressant and starting another within the same follow-up interval, but data were not gathered as to whether these occurred concurrently or separately within that period of time. Thus, some participants may have stopped one antidepressant and began another many months later, while others may have switched directly from one to another.
Kessler RC, Berglund P, Demler O et al (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National comorbidity survey replication. Arch Gen Psychiatry 62:593–602
Merikangas KR, He J-P, Burstein M et al (2010) Lifetime prevalence of mental disorders in U.S. adolescents: results from the national comorbidity survey replication–adolescent supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 49:980–989
Copeland WE, Angold A, Shanahan L et al (2014) Longitudinal patterns of anxiety from childhood to adulthood: the great smoky mountains study. J Am Acad Child Adolesc Psychiatry 53:21–33
Kendall PC, Safford S, Flannery-Schroeder E et al (2004) Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. J Consult Clin Psychol 72:276–287
Lopez B, Turner RJ, Saavedra LM (2005) anxiety and risk for substance dependence among late adolescents/young adults. J Anxiety Disord 19:275–294
Rudd MD, Joiner TE, Rumzek H (2004) Childhood diagnoses and later risk for multiple suicide attempts. Suicide Life Threat Behav 34:113–125
Woodward LJ, Fergusson DM (2001) Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry 40:1086–1093
Weisz JR, Kuppens S, Ng MY et al (2017) What five decades of research tells us about the effects of youth psychological therapy: a multilevel meta-analysis and implications for science and practice. Am Psychol 72:79–117
Walkup JT, Albano AM, Piacentini J et al (2008) Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 359:2753–2766
Rynn MA, Siqueland L, Rickels K (2001) Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158:2008–2014
The Research Unit on Pediatric Psychopharmacology anxiety study group (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279–1285
Birmaher B, Axelson DA, Monk K et al (2003) Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:415–423
Ginsburg GS, Becker EM, Keeton CP et al (2014) Naturalistic follow-up of youths treated for pediatric anxiety disorders. JAMA Psychiatry 71:310–318
Ginsburg GS, Becker-Haimes EM, Keeton C et al (2018) Results from the child/adolescent anxiety multimodal extended long-term study (CAMELS): primary anxiety outcomes. J Am Acad Child Adolesc Psychiatry 57:471–480
Swan AJ, Kendall PC, Olino T et al (2018) Results from the child/adolescent anxiety multimodal longitudinal study (CAMELS): functional outcomes. J Consult Clin Psychol 86:738–750
Piacentini J, Bennett S, Compton SN et al (2014) 24- and 36-Week outcomes for the child/adolescent anxiety multimodal study (CAMS). J Am Acad Child Adolesc Psychiatry 53:297–310
Clark DB, Birmaher B, Axelson D et al (2005) Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44:1263–1270
Rapaport MH, Wolkow R, Rubin A et al (2001) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104:289–298
Koran LM, Hackett E, Rubin A et al (2002) Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159:88–95
Wagner KD, Cook EH, Chung H et al (2004) Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13:53–60
Southammakosane C, Schmitz K (2015) Pediatric psychopharmacology for treatment of ADHD, depression, and anxiety. Pediatrics 136:351–359
Keeton CP, Kolos AC, Walkup JT (2009) Pediatric generalized anxiety disorder. Pediatr. Drugs 11:171–183
Pine DS (2004) Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 12:189–203
Pratt LA, Brody DJ, Gu Q (2017) Antidepressant use among persons aged 12 and over: United States, 2011–2014. NCHS Data Brief. Number 283. National Center for Health Statistics
Carey B (2018) Antidepressants and withdrawal. The New York Times, D3
Carey B, Gebeloff R (2018) The murky perils of quitting antidepressants after years of use. The New York Times, A1
Bushnell GA, Compton SN, Dusetzina SB et al (2018) Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications. J Clin Psychiatry. https://doi.org/10.4088/JCP.16m11415
Whiteside SP, Sim LA, Olsen MW et al (2019) The 5-year course of medication treatment in childhood anxiety disorders. J Clin Psychiatry. https://doi.org/10.4088/JCP.18m12318
Birmaher B, Brent D (2007) Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46:1503–1526
Cummings CM, Caporino NE, Kendall PC (2014) Comorbidity of anxiety and depression in children and adolescents: 20 years after. Psychol Bull 140:816–845
Ginsburg GS, Kendall PC, Sakolsky D et al (2011) Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol 79:806–813
Silk JS, Price RB, Rosen D et al (2019) A longitudinal follow-up study examining adolescent depressive symptoms as a function of prior anxiety treatment. J Am Acad Child Adolesc Psychiatry 58:359–367
Wolk CB, Carper MM, Kendall PC et al (2016) Pathways to anxiety–depression comorbidity: a longitudinal examination of childhood anxiety disorders. Depress Anxiety 33:978–986
Curry J, Silva S, Rohde P et al (2011) Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 68:263–269
Kendall PC, Hedtke KA (2006) Cognitive-behavioral therapy for anxious children: therapist manual, 3rd edn. Ardmore, PA
Compton SN, Walkup JT, Albano AM et al (2010) Child/adolescent anxiety multimodal study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health 4:1
Kendall PC, Compton SN, Walkup JT et al (2010) Clinical characteristics of anxiety disordered youth. J Anxiety Disord 24:360–365
Hollingshead AB (1975) Four factor index of social status. Yale University, New Haven, CT
Angold A, Costello EJ, Messer SB et al (1995) Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. Int J Methods in Psychiatr Res 5:237–249
Costello EJ, Benjamin R, Angold A et al (1991) Mood variability in adolescents: a study of depressed, nondepressed and comorbid patients. J Affect Disord 23:199–212
Wood A, Kroll L, Moore A et al (1995) Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note. J Child Psychol Psychiatry 36:327–334
Kent L, Vostanis P, Feehan C (1997) Detection of major and minor depression in children and adolescents: evaluation of the mood and feelings questionnaire. J Child Psychol Psychiatry 38:565–573
The Research Units on Pediatric Psychopharmacology Anxiety Study Group: The Pediatric Anxiety Rating Scale (PARS) (2002) Development and psychometric properties. J Am Acad Child Adolesc Psychiatry 41:1061–1069
Albano AM, Silverman WK (2006) Clinician’s guide to the anxiety disorders interview schedule for DSM-IV child and parent versions. Oxford University Press, New York
Howie LD, Pastor PN, Lukacs SL (2014) Use of medication prescribed for emotional or behavioral difficulties among children aged 6–17 years in the United States, 2011–2012 (No. 2014). US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics
This research was supported by the National Institute of Mental Health (NIMH) grants MH064089 to Dr. Ginsburg, MH064003 to Dr. Sokolsky, MH64088 to Dr. Piacentini, MH64092 to Dr. Albano, MH64107 to Dr. March, and MH063747 to Dr. Kendall. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Conflict of interest
Dr Kendall. received royalties from the sale of materials related to the treatment of anxiety in youth. He has also received support for his research from NIMH and NICHD. Dr. Birmaher. receives NIMH grants and royalties for books. Dr. Ginsburg. receives funding from NIMH and DOE, and has been a paid consultant for Syneos Health, Inc. in the past year Dr. Albano. receives royalties from Oxford University Press. Dr. Sokolsky receives funding from NIMH and a speaking fee from Northwell Health. Dr. Peris receives research funding from NIMH, PCORI, and the TLC Foundation for Body-Focused Repetitive Behaviors. She also receives royalties from Oxford University Press. Dr. Piacentini receives grant support from NIMH, TLC Foundation for BFRBs, and Pfizer Pharmaceuticals. He receives book royalties from Guilford Press and Oxford University Press. He received speaking/travel support from the International OCD Foundation, Tourette Association of America, and the TLC Foundation for BFRBs Ms. Frank is supported by a grant from NIMH. No other authors have any financial support or conflicts of interest to disclose.
Research Involving Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kagan, E.R., Frank, H.E., Norris, L.A. et al. Antidepressant Use in a 3- to 12-Year Follow-up of Anxious Youth: Results from the CAMELS Trial. Child Psychiatry Hum Dev 52, 41–48 (2021). https://doi.org/10.1007/s10578-020-00983-w